Top Page
Jubilant Pharmova Limited
(JUBLPHARMA)
Jubilant Pharmova Limited (JUBLPHARMA) vs. iShares MSCI India ETF (INDA)
Jubilant Pharmova Limited Business Overview & Revenue Model
Jubilant Pharmova Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.03B | 72.34B | 67.03B | 62.82B | 61.30B | 60.99B |
| Gross Profit | 48.11B | 46.99B | 43.52B | 42.00B | 46.42B | 45.63B |
| EBITDA | 11.46B | 10.48B | 7.93B | 6.46B | 10.66B | 14.68B |
| Net Income | 4.60B | 8.39B | 771.00M | -610.00M | 4.14B | 8.36B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 127.56B | 115.48B | 111.57B | 99.91B | 89.18B |
| Cash, Cash Equivalents and Short-Term Investments | 10.89B | 10.89B | 9.56B | 10.15B | 9.86B | 6.89B |
| Total Debt | 0.00 | 27.31B | 36.64B | 36.77B | 31.92B | 28.30B |
| Total Liabilities | -62.39B | 65.18B | 61.27B | 57.65B | 46.74B | 41.77B |
| Stockholders Equity | 62.39B | 62.55B | 54.34B | 53.99B | 53.19B | 47.41B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -435.00M | 736.00M | -1.54B | 2.38B | 12.57B |
| Operating Cash Flow | 0.00 | 10.72B | 9.71B | 6.61B | 8.38B | 17.84B |
| Investing Cash Flow | 0.00 | 4.88B | -6.08B | -5.44B | -3.80B | -7.39B |
| Financing Cash Flow | 0.00 | -14.53B | -4.33B | -1.57B | -325.99M | -17.09B |
Jubilant Pharmova Limited Technical Analysis
Jubilant Pharmova Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹137.70B | 28.70 | ― | 0.27% | -4.02% | -2.61% | |
72 Outperform | ₹146.90B | 8.65 | ― | 0.62% | 4.14% | 3.72% | |
69 Neutral | ₹146.83B | 24.94 | ― | 0.31% | 11.41% | 19.22% | |
67 Neutral | ₹225.89B | 128.25 | ― | 0.07% | -18.66% | -47.59% | |
62 Neutral | ₹188.15B | 39.16 | ― | 0.44% | 10.09% | -19.40% | |
60 Neutral | ₹181.16B | 28.56 | ― | 1.19% | 11.42% | -1.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Jubilant Pharmova Limited Corporate Events
Jubilant Pharmova Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The results, approved by the Board of Directors, were prepared in compliance with Indian Accounting Standards and SEBI regulations. The review by independent auditors concluded that the financial statements were presented fairly without any material misstatements, indicating stable financial management and compliance with regulatory standards.
Jubilant Pharmova Limited’s Board of Directors has approved the grant of 1,506 Stock Options/Restricted Stock Units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting employee motivation and aligning their interests with the company’s long-term goals.
Jubilant Pharmova Limited has announced the approval of 1,506 Stock Options/Restricted Stock Units (RSUs) for eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market positioning positively.
Jubilant Pharmova Limited has launched an initiative as part of the ‘Saksham Niveshak – 100 Days Campaign’ to assist shareholders in updating their KYC details and claiming unpaid dividends. This campaign, directed by the Ministry of Corporate Affairs, aims to prevent the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund Authority, ensuring shareholders secure their entitlements.
Jubilant Pharmova Limited has issued a second communication to its shareholders regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF). This move is in compliance with the Companies Act, 2013, and the IEPF Rules, which mandate the transfer of shares for which dividends have not been claimed for seven consecutive years. The company has reminded shareholders that unclaimed dividends from the financial year 2017-18 are due for transfer to the IEPF by November 1, 2025, unless there are specific legal restrictions. This action ensures compliance with regulatory requirements and affects shareholders who have not claimed their dividends, potentially impacting their equity holdings.
Jubilant Pharmova Limited has announced the publication of a newspaper advertisement related to several shareholder initiatives. These include the launch of the ‘Saksham Niveshak’ campaign by the Investor Education and Protection Fund Authority, a special window for re-lodgement of transfer requests for physical shares, and the updating of KYC and dematerialization of physical share certificates. This announcement is part of the company’s ongoing efforts to enhance shareholder engagement and streamline share-related processes.
Jubilant Pharmova Limited announced the successful completion of a USFDA pharmacovigilance inspection at its subsidiary, Jubilant Cadista Pharmaceuticals Inc., with no observations. This outcome underscores the company’s commitment to high standards of quality, safety, and compliance, reinforcing its strong position in the pharmaceutical industry.
Jubilant Pharmova Limited’s subsidiary, Jubilant Biosys Limited, has received three Orders-in-Appeal from the Additional Commissioner Central Tax (Appeals) in Mysuru, disallowing previously sanctioned GST refunds totaling Rs. 43.83 crore. The company plans to appeal these orders, arguing that the rulings are legally incorrect due to the omission of Rule 89(4B) from the CGST Rules and expects no financial or operational impact from this development.
Jubilant Pharmova Limited has announced the scheduling of its 47th Annual General Meeting (AGM) on August 29, 2025, which will be held virtually. The company has provided its shareholders with access to the AGM notice and the Annual Report for the financial year 2024-25 through electronic means, including a QR code for easy access. This move reflects the company’s commitment to maintaining transparency and engaging with its stakeholders effectively.
Jubilant Pharmova Limited has announced the dispatch of letters to shareholders whose email addresses are not registered, informing them about the availability of the Annual Report for FY 2024-25 and the Notice of the 47th Annual General Meeting (AGM) on the company’s website. The AGM is scheduled for August 29, 2025, and will be conducted via video conferencing, allowing shareholders to participate remotely. This move ensures compliance with regulatory requirements and enhances shareholder engagement by providing easy access to important company documents.
Jubilant Pharmova Limited has announced a final dividend of Rs. 5 per equity share for the fiscal year ending March 31, 2025, pending shareholder approval at the upcoming Annual General Meeting. The company has also communicated the tax implications of this dividend, highlighting that taxes will be withheld at varying rates based on shareholder status and provided documentation, with no tax for resident individuals receiving dividends under INR 10,000.
Jubilant Pharmova Limited has announced a special window for the re-lodgement of transfer requests for physical shares. This initiative, in compliance with SEBI regulations, aims to facilitate shareholders in updating their share transfer requests, potentially impacting the company’s shareholder engagement and compliance processes.
Jubilant Pharmova Limited has notified its shareholders about the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF) as per regulatory requirements. Shareholders with unclaimed dividends for seven consecutive years, starting from the financial year 2017-18, are urged to claim their dividends before the due transfer date of November 1, 2025, to avoid their shares being moved to the IEPF. This action underscores the company’s adherence to compliance regulations and impacts shareholders who have not claimed their dividends, potentially affecting their equity holdings.